Harvard Bioscience Inc
$ 6.08
-8.43%
12 Jun - close price
- Market Cap 27,421,900 USD
- Current Price $ 6.08
- High / Low $ 6.69 / 6.01
- Stock P/E N/A
- Book Value 2.23
- EPS -2.15
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.79 %
- 52 Week High 9.40
- 52 Week Low 3.75
About
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
Analyst Target Price
$6.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-12 | 2025-11-06 | 2025-08-11 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-07 | 2024-03-07 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.77 | -0.6383 | -0.03 | -0.1 | -0.1 | 0.06 | -0.2 | -0.0673 | 0.2 | 0.04 | 0.1 | 0.4 |
| Estimated EPS | -0.95 | 0.04 | 0.05 | -0.25 | -0.4 | 0.05 | 0.15 | 0.5 | 0.25 | 0.05 | 0.4 | 0.55 |
| Surprise | 0.18 | -0.6783 | -0.08 | 0.15 | 0.3 | 0.01 | -0.35 | -0.5673 | -0.05 | -0.01 | -0.3 | -0.15 |
| Surprise Percentage | 18.9474% | -1695.75% | -160% | 60% | 75% | 20% | -233.3333% | -113.46% | -20% | -20% | -75% | -27.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.21 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.2832258065 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HBIO
2026-06-12 16:08:44
Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units (RSUs) of common stock at no cost. These RSUs will vest either before the company's next annual meeting or one year from the grant date, whichever comes first. Following this transaction, Eade beneficially owns a total of 58,669 Harvard Bioscience shares, adjusted for a 10-for-1 reverse stock split that occurred on March 13, 2026.
2026-06-11 16:40:05
Harvard Bioscience director William Snider was granted 16,556 restricted stock units (RSUs) as compensation, which will vest either before the next annual meeting or one year from the grant date. This award increases his total holdings to 48,556 common share equivalents, including previously purchased shares and additional RSUs. The report also notes a 10-for-1 reverse stock split on March 13, 2026, which adjusted the number of some of Snider's prior RSU holdings.
2026-06-11 13:39:17
Harvard Bioscience (NASDAQ: HBIO) director Stephen J. Denelsky was granted 16,556 restricted stock units (RSUs) as reported in a Form 4 SEC filing. These RSUs will vest either immediately before the company's next annual meeting or one year from the grant date, serving as a time-based incentive. Following this award, Denelsky's total holdings in the company amount to 37,556 shares and RSUs, which also accounts for a 10-for-1 reverse stock split that occurred on March 13, 2026.
2026-06-11 13:39:17
Harvard Bioscience director Seth Benjamin Benson was granted 16,556 restricted stock units (RSUs) of common stock at a price of $0.0000 per share. These RSUs will vest either immediately before the company’s next annual meeting or one year from the grant date, whichever comes first. Following this grant, Benson directly holds 27,556 shares of common stock, which includes the new award and 11,000 previously beneficially owned shares, with all figures adjusted for a 10-for-1 reverse stock split on March 13, 2026.
2026-06-03 03:10:21
This article is a placeholder indicating that Harvard Bioscience announced its First Quarter 2026 Financial Results via an 8-K filing. The content displayed is merely a document placeholder, suggesting the detailed results would be within the actual 8-K filing.
2026-06-02 20:09:46
Harvard Bioscience, Inc. shareholders approved key proposals at their 2026 Annual Meeting, including an increase of 400,000 shares for their 2021 Incentive Plan and amendments to the Employee Stock Purchase Plan. Shareholders also re-elected two Class II directors, ratified Grant Thornton LLP as the independent auditor, and gave a non-binding advisory vote in favor of executive compensation. These actions reflect significant governance decisions and adjustments to employee equity programs for the coming years.
